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Background: Sleep complaints are highly prevalent in adolescents suffering from major depressive disorder (MDD).
The aims of this study were to describe the longitudinal course of sleep complaints, and to assess the association
between sleep complaints and clinical outcome in a sample of adolescents with MDD during naturalistic follow-up.
Methods: A sample of adolescent outpatients (n = 166; age 13–19 years, 17.5% boys) diagnosed with MDD was
followed-up during one year in naturalistic settings. Sleep symptoms and psychiatric symptoms were assessed with
interviews and self-report questionnaires.
Results: All sleep complaints were less frequent at one-year follow-up compared to baseline. Baseline sleep complaints
did not adversely affect clinical outcome at one-year follow-up: severity of the sleep complaints at baseline was
associated with a steeper improvement of depressive and anxiety symptoms, suicidality/self-harm symptoms, and
overall psychosocial functioning over time.
Conclusions: Our results suggest that sleep disturbances at baseline do not necessarily lead to poorer clinical
outcome during follow-up. Larger longitudinal studies combining both subjective and objective measures of
sleep in depressed adolescents are needed to clarify the link between sleep and depression further.
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Sleep complaints are highly prevalent in adolescents
suffering from major depressive disorder (MDD) [1,2].
The presence of sleep disturbances has been linked with
higher severity of depression, suicidal thoughts, comor-
bid anxiety disorders, and worse overall psychosocial
functioning [1-3]. During recovery from depression
sleep problems often persist: they rank among the most
common residual symptoms in both adult [4-6] and
adolescent patients [7-9].
In adults, subjectively and objectively measured sleep
disturbances have been identified as risk factors for
poor depression treatment outcome: they increase the
risk of nonremission [10,11] and recurrence [12,13].
Further, in adults, residual sleep symptoms have been* Correspondence: anna.urrila@helsinki.fi
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unless otherwise stated.associated with various aspects of impaired quality of
life, and residual nightmares have been associated with
suicidal ideation [14].
Adolescents differ from adults and children in terms
of both their natural sleep [15] and their typical charac-
teristics of depression [16]. In depressed adolescents, the
longitudinal course of sleep disturbances and their link
with other features of depression has not been extensively
studied. In a sleep polysomnography study of depressed
children and adolescents, decreased sleep efficiency and
delayed sleep onset predicted recurrences within one year
[17]. A temporal relationship between sleep problems and
completed suicide has also been observed in adolescents
[18]. It has been suggested that sleep abnormalities would
represent a persistent trait or vulnerability marker, rather
than being a state dependent feature of depression in
adolescents [19,20]. In a recent report, however, sub-
jectively reported sleep disturbances were highly related
to depressive state, and the persistence of sleep disturbance
during the treatment phase was positively associated withtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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hypothesized that the concurrent treatment of depression
and sleep disturbances in depressed adolescents would im-
prove both sleep and depression outcomes, possibly even
beyond the effects of traditional depression treatment [22].
Despite emerging new research, follow-up studies on
sleep symptoms in depressed adolescents still remain
scarce and knowledge on the extent to which sleep dis-
turbances are associated with clinical outcome in adoles-
cent depression remains limited. In particular, present
data comes mostly from treatment studies, and natural-
istic follow-up studies are lacking.
The aims of this study were: 1) to describe the longitu-
dinal course of sleep complaints, and 2) to assess the as-
sociation between sleep complaints and clinical outcome
in a sample of adolescent outpatients with MDD during
one-year naturalistic follow-up. We hypothesized 1) that
all sleep complaints would be less frequent after the
follow-up period compared to baseline,2) that sleep
complaints would be associated with depressive state,
poorer overall psychosocial functioning, anxiety symp-
toms, and suicidality/self-harm symptoms, and 3) that
baseline sleep complaints would adversely affect clinical
outcome.
Methods
Subjects
The sample comprised of n = 166 adolescent outpatients
meeting the DSM-IV criteria for major depressive dis-
order (MDD) at baseline. The subjects were part of a lar-
ger study population (Adolescent Depression Study,
ADS, n = 218) consisting of consecutive adolescent psy-
chiatric outpatients with any DSM-IV depressive mood
disorder diagnosis. As we were interested specifically in
the relationship between unipolar MDD and sleep, sub-
jects with any other depressive mood disorder diagnosis
than unipolar MDD (e.g. bipolar disorder, dysthymia)
were excluded from the analyses (n = 41). Further, sub-
jects in full remission already in baseline (n = 8) and sub-
jects with missing/inadequate data in baseline (n = 3)
were excluded, leaving n = 166 adolescents in the ana-
lyses presented in this paper. The exclusion criteria of
the ADS study included mental retardation, age under
13 or over 19 years, or insufficient knowledge of the
Finnish language. The recruitment procedure has been
described in detail in previous publications [23,24]. The
subjects and their legal guardian, in case the adolescent
was younger than 18 years, gave written informed con-
sent to participate. The study protocol was approved by
the ethics committees of Helsinki University Central
Hospital and Peijas Medical Health Care District.
At baseline, the subjects were 13–19 years old (mean ±
SD 16.5 ± 1.6 years), 17.5% of them were boys, and the
level of depression was mild in 21%, moderate in 20%,severe in 46% and partially remitted in 13%. Most adoles-
cents (70%) had at least one comorbid axis I diagnosis, of
which anxiety disorders were the most common (57% of
the adolescents). The sample characteristics as well as the
prevalence of sleep complaints at baseline have been previ-
ously described in detail [1,23,24].
The study was naturalistic in nature and thus the ado-
lescents received “treatment as usual” of clinically de-
fined duration during the one-year follow-up period.
Antidepressive medication was prescribed for n = 79
(55.6%) (serotonin selective reuptake inhibitors, SSRIs,
for n = 76), anxiolytic medication for n = 44 (31.0%),
nonbenzodiazepine sleep medication (z-drugs) for n = 25
(17.6%), and antipsychotic medication for n = 19 (13.4%).
A minimum of 10 appointments of individual supportive
psychotherapy was received by n = 112 (78.9%), and at
least one family counselling session was received by n =
72 (50.7%). The majority of the adolescents (85.2%) re-
ceived only outpatient treatment, but n = 15 (10.6%)
were hospitalized once to an adolescent psychiatric ward
and 6 adolescents had more than one period (2–4 pe-
riods) of hospital treatment.
The adolescents were re-evaluated approximately one
year later (time between baseline and one-year follow-up
386 ± 35 days; mean ± SD). N = 142 adolescents (85.5%
of the baseline sample; of which n = 24, 16.9% boys)
completed the follow-up interview. The adolescents who
did not attend the 1-year interview, did not show any
statistically significant differences in clinical or sociode-
mographic characteristics at baseline as compared to the
adolescents (n = 142) who completed the 1-year inter-
view. Sleep data for more than one item was missing for
n = 8 adolescents at the follow-up interview. At one-year
follow-up, n = 49 (29.5%) of the adolescents had remitted
from their baseline depressive episode with no recur-
rence, while n = 14 (8.4%) of the adolescents experienced
a recurrent depressive episode and n = 79 (47.6%) had
persistent depression. At one-year follow-up, two adoles-
cents were diagnosed as suffering from bipolar type II
disorder depressive episode, three from dysthymic dis-
order, and four from depressive disorder NOS.
Assessment of psychiatric symptoms
During baseline and one-year follow-up interviews, present
and lifetime episodes of DSM-IV axis I disorders were
assessed with Schedule for Affective Disorders and Schizo-
phrenia for School-Age Children—Present and Lifetime
version (K-SADS-PL) [25]. Remission of MDD was defined
according to the DSM-IV criteria as no significant signs or
symptoms of MDD present during at least the past two
months. Recurrence was defined as remission from the
baseline MDD episode and onset of a new MDD episode
[26,27]. The diagnoses (axis I-V) were confirmed in a diag-
nostic meeting where the original investigator and at least
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the interview, and inter-rater reliability was assessed using
13 randomly selected videotaped interviews (good inter-
rater reliability for mood disorder diagnoses; described in
detail previously [24].
Suicidality and self-harm symptoms were assessed as
part of the K-SADS-PL interview, which includes a total
of 5 items on suicidal thoughts, suicidal behaviour, and
non-suicidal self-harm. Any type of self-harm symptom,
when considered clinically significant in the interview,
was taken into account in the analyses.
To assess overall psychosocial functioning, the global
assessment of functioning scale (GAF; numeric range of
0–100) was used according to DSM-IV guidelines as part
of the DSM-IV axial diagnostic procedure [28] during
baseline and follow-up. GAF has been used also in stud-
ies among adolescents [29,30].
Anxiety symptoms were assessed with the Beck Anx-
iety Inventory (BAI) [31]. BAI is a 21-item self-report
measure of anxiety symptoms with a maximum score of
63 points. It has been validated both in adults and ado-
lescents [32,33].
The 21-item Beck Depression Inventory (BDI-21) is a
standardized 21-item questionnaire to measure depression
symptom severity [34]. It has been well studied also in ado-
lescents [35,36]. The adolescents were asked to rate each
of the symptoms on a 4-point scale ranging from 0 (Not at
all) to 3 (Severely) according to the severity of the symp-
tom (sum score range 0–63). In our analyses, the BDI-21
sleep item was excluded because we were looking at the
relationship between sleep and depression symptom sever-
ity, and consequently the maximum score for BDI-21 in
our analyses was 60 points. The Cronbach alpha value for
BDI-21 at baseline in our sample was 0.912 when the sleep
item was taken into account (21 items), and identical 0.912
when the sleep item was left out (20 items), showing that
internal consistency was not compromised when leaving
out the sleep item. The BDI-21 was performed during the
baseline and follow-up interviews. In addition, the BDI-21
was used according to the clinician’s judgement several
times between these two time points during the follow-up
period. Measurements performed between 0–400 days
from the baseline measurement were taken into account
in the analyses. A total of 1300 BDI-21 measurements, giv-
ing an average of 7.8 (range 1–37) measurements per sub-
ject were performed during the follow-up period.
Assessment of sleep complaints
The main source of information on sleep complaints was
the K-SADS-PL attachment for assessment of affective dis-
orders, which includes six items about the following sleep
symptoms: initial insomnia, middle insomnia, terminal
insomnia, sleep-wake rhythm disturbance, non-restorative
sleep, and hypersomnia. The interviewer rates eachsymptom as non-existent (score: 1), sub-threshold (score:
2), or clinically significant (score: 3) according to standard
criteria [1]. Insomnia was defined as suffering from clinic-
ally significant initial, middle, or terminal insomnia, or sev-
eral of these insomnia symptom subtypes.
Additionally, we assessed nightmares as part of the 36-
item General Health Questionnaire (GHQ-36) (answer-
ing scale: no – not more than usual – slightly more than
usual – much more than usual) [37,38], since the pres-
ence of frequent nightmares has been previously linked
with suicidality [39-41].
Statistical analyses
Statistical analyses were performed with the IBM SPSS
Statistics Version 21. To assess cross-sectional differences
between subgroups, Chi-square tests and independent
samples t-tests were used as appropriate. McNemar’s tests
were used as non-parametric tests for categorical variables
when comparing related samples (baseline vs. follow-up).
A series of multiple linear regression analyses using the
generalized estimating equations (GEE) method was con-
ducted to assess whether sleep complaints at baseline were
associated with clinical outcome measures (depression
symptom severity, suicidality/self-harm symptoms, overall
psychosocial functioning, anxiety symptoms) at follow-up.
This method takes into account the within-subject correl-
ation across repeated measurements [42]. For all analyses,
a p-value of <0.05 was considered statistically significant.
Results
Prevalence of sleep complaints at follow-up
The sleep complaints at baseline have been described in
detail in our previous paper [1]. At one-year follow-up,
clinically significant sleep complaints (K-SADS-PL score:
3) were observed in 50.0% (n = 67) of the adolescents.
The other half (n = 67) of the adolescents were free of clin-
ically significant sleep complaints. The most frequent clin-
ically significant sleep complaint (39.3% of the adolescents)
at follow-up was non-restorative sleep. At follow-up, 13.4%
(n = 18) of the adolescents suffered from a combination of
several sleep disturbances (two or more of the following:
insomnia, hypersomnia, sleep-wake rhythm disturbance).
At the group level, all sleep complaints were less fre-
quent at follow-up compared to baseline (McNemar’s
tests p < 0.05) except for sleep-wake rhythm distur-
bance, in which the difference was close to but did not
reach statistical significance (McNemar’s test p = 0.084).
Sleep complaints and other features of depression at
follow-up
At follow-up, sleep complaints were mainly observed in
adolescents with persistent or recurrent depression
(Figure 1). Sleep complaints were very rare in patients
who had remitted from their baseline MDD episode:
Figure 1 The prevalence (% of the total sample; n = 142) of different sleep complaints among adolescents with MDD at baseline and
at one-year follow-up. The adolescents are grouped according to MDD status (remission, recurrent, persistent) at 1-year follow-up. Insomnia
represents any significant complaints of insomnia (initial, middle or terminal). At one-year follow-up, sleep data for more than one item was
missing for n = 8 adolescents.
Urrila et al. BMC Psychiatry 2014, 14:283 Page 4 of 9
http://www.biomedcentral.com/1471-244X/14/283only three of them suffered from insomnia, two from non-
restorative sleep, one from hypersomnia, and one from fre-
quent nightmares. The recurrent and persistent subgroups
did not differ from each other in terms of any sleep com-
plaint (χ2 tests n.s.) except for middle insomnia, which was
more common in adolescents with recurrent depression
(χ2 = 8.37, p = 0.013).
At follow-up, adolescents suffering from any significant
sleep complaint (n = 67) had higher scores in the BDI-21
(independent samples t-test t = 5.81; p <0.001) and BAI (t =
4.67; p < 0.001), and suffered more frequently from suicida-
lity/self-harm symptoms (χ2 = 7.31, p = 0.006) compared to
adolescents without sleep complaints (n = 67). No statisti-
cally significant difference was found in overall psychosocial
functioning between these two subgroups (t = −8.37; p =
0.194). Suicidality/self-harm symptoms at follow-up were
not connected with having much more nightmares than
usual at follow-up or with having much more nightmares
than usual at baseline (χ2 tests n.s.).
The association of baseline sleep complaints with one-year
clinical course
GEE models were used to investigate the association of
baseline sleep complaints with depression severity, overallpsychosocial functioning, anxiety symptoms, and suicidal-
ity/self-harm symptoms over time. For these analyses, we
used the total sum of all six K-SADS sleep item scores at
baseline (1–3 points per item, minimum 6 points, max-
imum 18 points; missing answers were substituted with
the average points of all items) to form a continuous meas-
ure of sleep complaints (sleep complaint severity score).
Age and gender were controlled in the analyses.
Main effects of sleep complaints were observed on the
following outcomes: depression symptom severity (β =
1.15, standard error (SE) = 0.344, p = 0.001), anxiety symp-
toms (β = 1.03, SE = 0.373, p = 0.006), overall psychosocial
functioning (β = −0.923, SE = 0.331, p = 0.005), and suicid-
ality/self-harm symptoms (OR = 1.31, 95% Wald confi-
dence interval (CI) [1.15-1.50], p < 0.001). Age was
negatively associated with suicidality/self-harm symptoms
(OR = 0.770, CI [0.640-0.927], p = 0.006), and female gen-
der was associated with higher severity of depression (β =
2.95, SE = 1.29, p = 0.022).
An interaction between time and sleep complaint se-
verity score was found in depression symptom severity
(β = −1.36, SE = 0.364, p < 0.001), anxiety symptoms
(β = −0.967, SE = 0.359, p = 0.007), overall psychosocial
functioning (β = 1.50, SE = 0.457, p = 0.001), and suicidality/
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0.001). (Table 1) These interactions indicate that the more
the adolescent had sleep complaints at baseline, the quicker
was the clinical improvement (steeper decline in depres-
sion/anxiety symptoms and suicidality/self-harm, as well as
steeper improvement in overall psychosocial functioning).
All reported results concerning the effects of sleep
complaints on clinical outcomes (main effects and inter-
actions) remained significant also in additional analyses
controlling for the baseline values of the outcomes.
The use of antidepressants, use of anxiolytics, use of
antipsychotics, use of nonbenzodiazepine sleep medica-
tion (z-drugs), the amount of treatment appointments
(cutoff ≥10 treatment appointments) during the 1-year
follow-up period, or the amount of comorbid psychiatric
disorders was not associated with the baseline sleep
complaint severity score (independent samples t-tests
n.s.). The adolescents who dropped out during follow-up
(n = 24) did not differ from the adolescents who com-
pleted the 1-year interview (n = 142) in terms of their
baseline sleep complaint severity score (independent
samples t-test n.s.).Rate of depression symptom improvement
To assess the recovery process in more detail, the effects
of baseline sleep complaint severity on the changes in
the repeated BDI-21 measurement scores during the
follow-up period were assessed with a GEE-model. Age
and gender were controlled; female gender was associ-
ated with higher BDI-21 scores, while age showed no
significant effect. Sleep complaint severity score at base-
line showed a major effect on BDI-21 score. An inter-
action between time and sleep complaint severity score
was observed (β = −0.003, SE = 0.0012, p = 0.028), indi-
cating a significantly steeper decline in depression symp-
tom severity over time in adolescents with higher sleep
complaint severity score (Figure 2).Table 1 Statistics on interactions between time and sleep
complaint severity score (GEE model interactions)
β/OR SE/CI p
BDI-21
time*sleep complaint severity score −1.36 0.364 <.001*
BAI
time*sleep complaint severity score −0.967 0.359 .007*
GAF
time*sleep complaint severity score 1.50 0.457 .001*
suicidality/self-harm
time*sleep complaint severity score 0.681 [0.561-0.826] <.001*
*denotes p-values <0.05, which were considered statistically significant.Discussion
This is one of the first naturalistic clinical follow-up
studies of depressed adolescents assessing the link be-
tween sleep complaints and clinical outcome. As hy-
pothesized, all sleep complaints were less frequent after
the one-year naturalistic follow-up period compared to
baseline, and sleep complaints were associated with de-
pressive state, poorer overall psychosocial functioning,
anxiety symptoms, and suicidality/self-harm symptoms.
Contrary to our expectations, however, baseline sleep
complaints did not adversely affect clinical outcome at
one-year follow-up.
Sleep complaints at follow-up were mainly observed in
adolescents with persistent or recurrent depression and
they were very rare in patients who had remitted from
their baseline MDD episode. These findings support the
tight link between sleep complaints and depressive state
[21].
Residual sleep symptoms in adolescents who had re-
mitted from depression were very rare. This result is in
line compared to previous reports showing a ~3-12%
prevalence of insomnia/sleep symptoms in adolescents
remitted from depression [7,8,21]. Methodological differ-
ences, especially the length of the follow-up period
(12 weeks of acute treatment vs. 1 year naturalistic clin-
ical follow-up) may explain the dispersion of the results.
A shorter follow-up time may not capture the full im-
provement of sleep symptoms over time. The compari-
son between different studies is also complicated by the
heterogeneous ways of measuring and defining sleep dis-
turbances. Our quite conservative method of assessing
sleep disturbances, especially insomnia, may also have
affected the results to some extent [1]. In our sample,
sub-threshold residual sleep symptoms were approxi-
mately as common as having clinically significant sleep
complaints among adolescents who had remitted from
their baseline MDD episode (sub-threshold symptoms of
insomnia were observed in n = 4 (9.30%), sub-threshold
hypersomnia in n = 5 (11.6%), and sub-threshold sleep-
wake rhythm disturbances in n = 2 (4.65%)).
Adolescents’ self-reported sleep estimates do not al-
ways correlate with objective measures of sleep [43-46].
It can be speculated that objective sleep abnormalities
(like shortened REM sleep latency) previously reported
in depressed children and adolescents in stable recovery
[19] might have been present in our remitted subjects
even in the absence of subjective sleep complaints. This
possibility cannot be ruled out, but based on previous
reports it seems, however, unlikely since even in the
presence of subjective sleep complaints, sleep EEG has
not been objectively disturbed in depressed children and
adolescents [46]. The use of the K-SADS-PL to assess
sleep disturbances is not the ideal approach to assess
sleep disturbances, but it has been successfully used in
Figure 2 BDI-21 total scores (sleep item excluded) during the follow-up period up to 400 days. Black dots indicate subjects with a sleep
complaint severity score of 6–9 (n = 52), blue dots indicate subjects with a sleep complaint severity score of 10–13 (n = 83), and red dots indicate
the subjects with a sleep complaint severity score of 14–18 (n = 31) at baseline interview. Loess curves with respective colours are fitted for each
of these sleep subgroups.
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information on some aspects of sleep. Subjective mea-
sures of sleep are clinically useful and they convey the
patient’s own experience of sleep.
Having many sleep complaints at baseline, although
linked with a less favourable baseline status, was associ-
ated with a significantly quicker improvement of depres-
sion and anxiety symptoms and overall psychosocial
functioning over time. This result was surprising because
in previous studies in adults sleep disturbances have
been identified as risk factors for poor depression treat-
ment outcome. It is possible that the relationship be-
tween sleep and depression differs between adults and
adolescents and is influenced by e.g. maturational factors
and factors related to the stage of illness. It seems likely
that clinical features other than disturbed sleep (includinge.g. axis II comorbidity, MDD episode duration, excessive
alcohol use) determined the one-year clinical outcome in
our sample [23,48,49].
Differences in attrition rates, treatment efficacy or axis
I comorbidities associated with sleep complaint severity
could have influenced our findings. There were, however,
no significant association between sleep complaint sever-
ity score and attrition rate, the amount of comorbid axis
I disorders, or treatment received in our sample. The
study was naturalistic in nature and treatment was not
randomly assigned but planned according to clinical
judgement, allowing also targeting treatment to sleep
disturbances when necessary. Yet, no association be-
tween sleep complaint severity score and nonbenzodia-
zepine sleep medication (z-drugs) was observed. This
may be explained by the fact that, apart from z-drugs
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sleep problems in our sample), many other groups of
medications (such as benzodiazepines, sedative neuro-
leptics, mirtazapine, hydroxyzine etc.) may have been
used to ameliorate sleep. Unfortunately we do not have
data on the precise condition for which each medication
was prescribed (e.g. a benzodiazepine may have pre-
scribed to treat daytime anxiety or insomnia). At the
time of data collection, no systematic sleep-related non-
medication treatments (such as cognitive behavioural
therapy for insomnia or chronotherapeutic treatments)
were used in the Finnish adolescent psychiatric treat-
ment units, but the adolescents may have been given ad-
vice on e.g. sleep hygiene measures during the treatment
appointments.
Depressed patients with sleep disturbances may respond
differently to both pharmacological and other treatment of
depression compared to those without sleep problems
[11,50-52]. The more detailed findings remain, however,
mixed, and research evidence is lacking. Antidepressant
drugs may ameliorate the sleep impairments in depression
by e.g. inhibiting REM sleep [53], and especially patients
with reduced REM sleep latency may respond favourably
to antidepressants [54]. In a preliminary study, however,
fluoxetine had a negative impact on sleep in depressed
children and adolescents [55]. Depressed adolescents
reporting insomnia have been observed to be less likely to
respond to antidepressant treatment than those without
insomnia [52]. In addition, depressed adolescents receiving
medication for sleep have been found to respond less likely
to depression treatment than those without sleep medica-
tion [51]. The low response rate of adolescents treated
with sleep medication has been particularly associated with
the use of trazodone (NB trazodone was not in use among
our study sample), pointing towards drug-specific effects.
[51] Further, the wide range of sleep disturbances (e.g.
insomnia vs. hypersomnia) may interact with various
depression treatments differently. Although the use of
medication was not associated with sleep complaint
severity score in our sample, we can not rule out
the possibility that individuals with different types of
sleep complaints may have responded differently to
prescribed medications.
It has been suggested that joint treatment of dis-
turbed sleep and depression may be more effective than
treatment of depression alone [22]. The good one-year
clinical outcome of our adolescents with baseline sleep
disturbances may have been partly influenced by the
naturalistic nature of the study: individual treatment
choices were made based on the clinical picture, which
allows taking also the precise characteristics of sleep
symptoms into account. At the same time, though, in
the naturalistic setting, the medication and other treat-
ments received by the participants could not be tightlycontrolled, which complicates the interpretation of the
data.
The relationship between sleep and mood is complex
and bidirectional. One possibility is that at least for some
of the adolescents the sleep disturbance may have been
the driving force for depression, and the resolution of
sleep problems may have also resulted in a reduction of
depression symptoms.
Among the strengths of this study are the sample of
clinically very well characterized subsequent outpatients,
the naturalistic setting, the use of standardized evalu-
ation instruments, and the homogenous age range. The
study was not primarily designed to study sleep distur-
bances, but mood disorders. Thus, it did not include any
objective characterization of sleep or any sleep-specific
questionnaires, but we used the K-SADS-PL as the main
source of information on sleep. This is the major limita-
tion of the study. Further, we did not have explicit infor-
mation on the sleep-related treatments the patients may
have received during the follow-up period. Other limita-
tions include the unequal gender distribution and the
relatively small sample size.
Conclusions
Our findings point toward a close link between sleep
disturbances and depressive state in adolescents with
MDD. Severity of baseline sleep complaints did not have
an unfavorable effect on clinical outcome in a one-year
naturalistic clinical follow-up, suggesting that sleep dis-
turbances at baseline do not necessarily lead to poorer
clinical outcome during follow-up. Larger longitudinal
studies combining both subjective and objective (e.g.
polysomnographic/actigraphic) measures of sleep in de-
pressed adolescents should be conducted to clarify the
link between sleep and depression in adolescents in fur-
ther detail. Studies focusing on the management of the
various sleep disturbances in depressed adolescents are
also needed.
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